Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 200,000 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 200,000 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $80.57, for a total value of $16,114,000.00. Following the transaction, the chief executive officer directly owned 809,631 shares in the company, valued at approximately $65,231,969.67. The trade was a 19.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Down 3.1%

Shares of NASDAQ:TEM traded down $2.52 during trading on Friday, hitting $77.84. The company’s stock had a trading volume of 9,310,212 shares, compared to its average volume of 7,226,184. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The business has a 50 day moving average price of $57.19 and a two-hundred day moving average price of $52.90. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The company has a market capitalization of $14.04 billion, a PE ratio of -54.06 and a beta of 3.72.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same period in the previous year, the firm posted ($0.22) EPS. Tempus AI’s revenue for the quarter was up 21.6% on a year-over-year basis. As a group, research analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. WINTON GROUP Ltd acquired a new position in Tempus AI in the 2nd quarter valued at about $342,000. Engineers Gate Manager LP acquired a new position in shares of Tempus AI in the second quarter valued at approximately $637,000. Integrated Wealth Concepts LLC acquired a new position in shares of Tempus AI in the second quarter valued at approximately $145,000. Baird Financial Group Inc. raised its stake in shares of Tempus AI by 3.4% during the second quarter. Baird Financial Group Inc. now owns 30,434 shares of the company’s stock worth $1,763,000 after purchasing an additional 994 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of Tempus AI by 13.3% during the second quarter. Arizona State Retirement System now owns 28,867 shares of the company’s stock worth $1,672,000 after purchasing an additional 3,384 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Wall Street Analysts Forecast Growth

TEM has been the subject of a number of research analyst reports. Wolfe Research began coverage on Tempus AI in a report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Lake Street Capital downgraded shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. HC Wainwright increased their target price on shares of Tempus AI from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, September 11th. Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 11th. Finally, UBS Group began coverage on shares of Tempus AI in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 price target for the company. Eleven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $69.33.

About Tempus AI

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.